Phenominer Database Results (13 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Experiment Notes Record ID Study ID
LEW.1F percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 100.0 % in vivo visual assessment 0.0 0 69677 1159
LEW.1F percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84520 1178
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 8 18.0 d 1.0 2.83 in vivo visual assessment 0.0 0 69818 1163
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 100.0 % in vivo visual assessment 1.296E7 0 70129 1282
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait female 56 days-84 days 8 100.0 % in vivo visual assessment 0.0 0 69814 1163
LEW.1F subjects with ankylosis to total subjects with arthritis ratio pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 0.0 % in vivo visual assessment tail 1.296E7 0 70135 1282
LEW.1F percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 50.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84534 1178
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 14 86.0 % in vivo visual assessment 0.0 0 69813 1163
LEW.1F arthritic paw count pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 3.4 null 0.21 0.7 in vivo visual assessment tail 1.296E7 0 70138 1282
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68. joint integrity trait both 56 days-234 days 11 17.0 d 0.9 3.0 in vivo visual assessment 1.296E7 0 70133 1282
LEW.1F percentage of study population developing experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 100.0 % in vivo visual assessment 0.0 0 69661 1159
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 17.0 d 1.26 4.0 in vivo visual assessment 0.0 0 69669 1159
LEW.1F post-insult time to onset of experimental arthritis pristane (150 ul) Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83. joint integrity trait male 56 days-84 days 14 31.0 d 7.0 26.19 in vivo visual assessment 0.0 0 69817 1163